Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Claudin18.2 Proteins

Claudin18.2 Proteins

Claudin18_2
INTRODUCTION

           Strcture of Claudin18.2 (AlphaFold structure prediction)
Claudin is a family of proteins first discovered by Furuse in 1998 , which contains at least 27 members. It’s a type of four-pass transmembrane protein that expressed at the tight junction of epithelium and endothelium which is a component of tight junction strands that play critical roles in maintaining cell polarity and signal transductions. Claudin18.2, the subtype of Claudin18, is reported only limitedly expressed in differentiated epithelial cells of the gastric mucosa whereas significantly expressed in a variety of malignant tumor tissues such as gastric cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer and lung cancer etc. Thus it has emerged as an ideal target for immunotherapy including monoclonal antibody, bispecific antibody, ADC and CAR-T therapy.
Restricted by the surface area of the cell membrane and the potential cytotoxicity of overexpressed membrane proteins, the expression level of recombinant four-pass Claudin18.2 proteins is much lower than that of soluble proteins. Furthermore, it is necessary to screen suitable detergents or lipids  to maintain spatial conformation and protein activity in the process of extraction and purification. So that makes it very difficult to obtain Claudin18.2 antigen with high purity, native conformation and activity, which seriously hinders the development of drugs and therapies targeting Claudin18.2.
Relying on the technology platforms of multi-pass transmembrane proteins, ACROBiosystems has successfully developed full-length Claudin18.2-VLP and Claudin18.2-DDM/CHS , and their high biological activity is verified by ELISA/BLI/SPR which meets the requirements of drug development. Meanwhile, the high-quality integrated SPR&BLI service with Claudin18.2 is provided for antibody screening, characterization, and consistency evaluation to meet the needs of drug development, assist drug clinical declaration.
PRODUCT LIST
PRODUCT FEATURE

The following ELISA/SPR/BLI protocols are available for free.

Full-length Claudin18.2-VLP
(CL2-H52P7CL2-HF218)
Claudin18.2-VLP
Advantages
Full-length Claudin18.2
Enhanced humoral and cellular immune responses
Optimal target presentation to APC and phage display because of its 100-300nm in size
Suitable for immunization/ELISA/SPR/BLI/cell-based assay /CAR detection
Exclusive Claudin18.2-DDM/CHS
(CL2-H82E3CL2-H5587)
Nanodisc Platform
Advantages
Claudin18.2 with complete conformation
Can be accurately quantified
High solubility in presence of DDM/CHS (DC-11)
Biotinylated Claudin18.2 (CL2-H82E3) is available
Suitable for immunization/ELISA/SPR/BLI

Claudin18.2-VLP

Correct assembly validated by SEM
Full-length Claudin18.2-VLP (Cat. No.CL2-H52P7) has been observed under an electron microscope to ensure that it is assembled correctly.
Claudin18.2-VLP
High bioactivity validated by ELISA
ELISA

Immobilized Human Claudin-18.2 Full Length Protein-VLP (Cat. No. CL2-H52P7) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.2-3 ng/mL (QC tested).

High affinity validated by SPR
SPR

Human Claudin-18.2 Full Length Protein-VLP (Cat. No. CL2-H52P7) captured on CM5 Chip via Anti-Claudin-18.2 antibody can bind Anti-Claudin-18.2 antibody with an affinity constant of 0.374 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Suitable for CAR detection
Good bioactivity validation of CD20-DDM/CHS

2e5 of Anti-Claudin-18.2 CAR-293 cells were stained with 100 μL of 3 μg/mL of Fluorescent Human Claudin-18.2 Full Length Protein-VLP (Cat. No.CL2-HF218) and negative control protein respectively, FITC signals was used to evaluate the binding activity (Routinely tested).

Exclusive Claudin18.2-DDM/CHS

High bioactivity validated by ELISA
Good bioactivity validation of full-length CD20-DDM/CHS

Immobilized Human Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5587) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

High affinity validated by SPR
Good bioactivity validation of CD20-DDM/CHS

Anti-Claudin-18.2 mAb captured on CM5 chip via anti-Human IgG (Fc) antibody can bind Human Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5587) with an affinity constant of 6.72 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

CLINICAL DRUG INFORMATION
NameResearch CodeResearch PhaseCompanyIndicationsClinical Trials
REFERENCES

Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature (2021)

Furuse M, et al. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin[J]. J Cell Biol(1998)

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message